Holen Sie sich die Stockscreener-App
24.57
2.07%
-0.52
Handel nachbörslich:
24.08
-0.49
-1.99%
Schlusskurs vom Vortag:
$25.09
Offen:
$24.81
24-Stunden-Volumen:
167.12K
Relative Volume:
2.00
Marktkapitalisierung:
$1.48B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.84M
KGV:
-5.3764
EPS:
-4.57
Netto-Cashflow:
$-6.73M
1W Leistung:
+1.24%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$24.35
$26.14
1-Wochen-Bereich:
$24.00
$27.01
52-Wochen-Spanne:
$16.50
$27.68
Damora Therapeutics Inc Stock (DMRA) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
(781) 281-9020
Adresse
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
24.57 | 1.51B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2026-02-17 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - marketbeat.com
Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 8.5%What's Next? - MarketBeat
Did Damora’s New Biopharma Heavyweight Leadership Just Reshape Damora Therapeutics' (DMRA) Investment Narrative? - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
DMRA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
New Damora CEO gets 2 million-share hiring package under Nasdaq rule - Stock Titan
ETFs Investing in Damora Therapeutics, Inc. Stocks - TradingView
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update - marketbeat.com
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
DMRA (Damora Therapeutics) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
DMRA PE Ratio & Valuation, Is DMRA Overvalued - Intellectia AI
DMRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 9.6%Time to Sell? - MarketBeat
Damora Therapeutics Inc (DMRA) Stock Earnings Transcripts - gurufocus.com
Damora Therapeutics Inc (DMRA) Stock Price & 30 Year Financial Data - gurufocus.com
This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Damora Therapeutics (DMRA) grants 250,000 stock options to General Counsel - Stock Titan
Damora Therapeutics director granted 37,313 options | DMRA Insider Trading - Stock Titan
Damora Therapeutics (DMRA) director receives 37,313-share stock option grant - Stock Titan
Damora Therapeutics (DMRA) insiders receive 37,313-share option grant via Fairmount - Stock Titan
Damora Therapeutics (DMRA) director option grant tied to Fairmount funds - stocktitan.net
Damora Therapeutics (DMRA) director awarded 37,313 stock options - Stock Titan
Damora Therapeutics (DMRA) director files Form 3 initial ownership report - Stock Titan
Damora Therapeutics (NASDAQ: DMRA) director Michael Landsittel files Form 3 - Stock Titan
Damora Therapeutics Inc (DMRA) DCF Valuation - GuruFocus
Damora Therapeutics Inc (DMRA) Insider Trading Activity | Apple Insider Buys and Sells - gurufocus.com
Evercore ISI Group Initiates Coverage on DMRA with 'Outperform' - gurufocus.com
Evercore ISI initiates Damora Therapeutics stock with outperform By Investing.com - Investing.com India
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns Outperform Rating from Analysts at Evercore - marketbeat.com
Evercore ISI initiates Damora Therapeutics stock with outperform - Investing.com
Finanzdaten der Damora Therapeutics Inc-Aktie (DMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Damora Therapeutics Inc-Aktie (DMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
| Schambye Hans T. | Chief Executive Officer |
Jul 03 '25 |
Sale |
3.38 |
735 |
2,484 |
4,022 |
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):